This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
5 Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was mixed last week. The Nasdaq and the S&P 500 hit a new all-time high on the artificial intelligence boom and the Fed rate cut bets.
Top & Flop ETF Areas of Wall Street's Best February in Decade
by Sanghamitra Saha
Wall Street surged to close out February with the S&P 500 and Nasdaq Composite notching their best February since 2015.
Best-Performing ETFs of Last Week
by Sanghamitra Saha
The S&P 500 hit a new high for the year last week after the November jobs report and University of Michigan consumer survey data indicated a resilient economy and cooling inflation, triggering bets on a so-called soft-landing scenario.
Top and Flop Industry ETFs of Q3
by Sanghamitra Saha
The third-quarter was an average-to-downbeat period for investors, mainly due to rising rates.
4 Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street offered a moderate-to-downbeat performance last week.
ETFs to Play Biden's 2024 Reelection Campaign Launch
by Sanghamitra Saha
President Joe Biden recently announced his reelection bid. These ETF areas may benefit on that campaign launch.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street offered a flat performance last week. Biotech, platinum and home building were some of the areas that won last week.
3 ETF Areas Likely to be in Tight Spots Post Banking Crisis
by Sanghamitra Saha
Wall Street has been witnessing the biggest banking meltdown since 2008. These ETF investing areas are at tight spots.
What Slump? 4 Sector ETFs Up At Least 14% in Q3
by Sanghamitra Saha
Though Wall Street delivered a subdued performance in Q3, these sector ETFs offered double-digit returns.
4 Best ETF Areas of Last Week That Are Up At Least 5%
by Sanghamitra Saha
Wall Street was downbeat last week led by Apple after it dropped plans to boost production of its new iPhones.
5 Best Areas of Q3 of 2022 & Their Top ETFs
by Sanghamitra Saha
These ETF areas won in the third quarter of 2022.
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Stocks' Best Month Since 2020: Top ETF Areas of July
by Sanghamitra Saha
Wall Street logged the best month since November 2020 in July. These are the winning ETFs.
3 ETFs Braving Inflationary Fears in Past Three Months
by Sanghamitra Saha
These ETFs have braved the inflationary fears in the past three months and topped the S&P 500.
The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO
by Zacks Equity Research
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
5 ETFs Riding High on the Biotech Comeback
by Sweta Killa
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Pharma & Biotech ETFs at One-Month High: Here's Why
by Sanghamitra Saha
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
4 Sector ETFs That Survived Market Turmoil in June
by Sweta Killa
June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed¿¿¿s aggressive tightening policy are weighing heavily on investors' sentiment.
ETFs Winners of S&P 500's Second Best Week in 2022
by Sanghamitra Saha
The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.
Top and Flop ETFs of Q1
by Sweta Killa
We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.
Top and Flop ETFs At Midway Q1
by Sweta Killa
We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal
by Sweta Killa
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.